US Family Health Plan Prior Authorization Request Form for **Bimekizumab-bkzx (Bimzelx, Bimzelx autoinjector)**

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to: Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? Call 1-877-880-7007

Prior authorization does not expire.							
Step	Please comp	lete patient and physician information (p	lease print):				
1	Patient Name	: Phy	vsician Name:				
	Address:		Address:				
	Sponsor ID #		Phone #:				
	•		Secure Fax #:				
Step	Please com	plete the clinical assessment:					
2	1. Is the	patient 18 years of age or older?	□ Yes	🗆 No			
			Proceed to question 2	STOP			
				Coverage not approved			
	2. What	is the diagnosis or indication?	moderate to severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy- Proceed to question 3				
			□ ankylosing spondylitis (AS) - Proceed to question 4				
			□ non-radiographic axial spondyloarthritis with objective signs of inflammation (nr-AxSpA) - Proceed to question 4				
			□ psoriatic arthritis - Proceed to question 3				
			□ Other diagnosis or indication – STOP Coverage not approved				
		Has the patient had an inadequate response to non-biologic systemic therapy? (For example: methotrexate, aminosalicylates [such as, sulfasalazine, mesalamine], corticosteroids, immunosuppressants [for example., azathioprine], etc.)	□ Yes	🗆 No			
			Proceed to question 5	STOP			
	sulfas immu			Coverage not approved			
		Has the patient had an inadequate response to at least two Nonsteroidal anti-inflammatory drugs (NSAIDs) over a period of at least two months?	□ Yes	🗆 No			
			Proceed to question 5	STOP			
				Coverage not approved			

5.	Humira is the Department of Defense's preferred targeted biologic agent. Has the patient tried	□ Yes	□ No
	Humira?	Proceed to question 6	Proceed to question 8
6.	Has the patient had an inadequate response to	□ Yes	🗆 No
	Humira?	Proceed to question 9	Proceed to question 7
7.	Has the patient experienced an adverse reaction	□ Yes	🗆 No
	to Humira that is not expected to occur with the requested agent?	Proceed to question 9	STOP
			Coverage not approved
8.		□ Yes	🗆 No
	Humira (adalimumab)?	Proceed to question 9	STOP
			Coverage not approved
9.	Has the patient tried and experienced an inadequate response, had an adverse reaction, or have a contraindication to Stelara	□ Yes	🗆 No
		Proceed to question 10	STOP
	(ustekinumab)?		Coverage not approved
10.	Has the patient tried and experienced an	□ Yes	🗆 No
	inadequate response, had an adverse reaction, or have a contraindication to Cosentyx	Proceed to question 11	STOP
	(secukinumab)?		Coverage not approved
11.	Will the patient be receiving any other targeted immunomodulatory biologics with bimekizumab,	□ Yes	□ No
	including but not limited to the following:TNF	STOP	Sign and date below
	inhibitors, IL-1, IL-6, IL-17, IL-23, IL-36, JAK inhibitors?	Coverage not approved	

Step I certify the above is true to the best of my knowledge. Please sign and date: 3

Prescriber Signature

Date

[05 Dec 2024]